BridgeBio Pharma (NASDAQ:BBIO) Given New $45.00 Price Target at Bank of America
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...
pharmaphorum1d
BridgeBio poised to challenge Pfizer after Attruby approval
The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although, ...
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM ...
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Acquired by Massachusetts Financial Services Co. MA
Massachusetts Financial Services Co. MA lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 23.3% in ...
BridgeBio Pharma’s Acoramidis Approval and Competitive Pricing Strategy Boosts Positive Stock Outlook
David Lebowitz, an analyst from Citi, maintained the Buy rating on BridgeBio Pharma (BBIO – Research Report). The associated price target ...
FiercePharma1d
Look out, Pfizer: BridgeBio scores 'best-case' FDA nod for Attruby in cardiomyopathy
On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday
On Friday, the FDA approved BridgeBio Pharma's Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer ...
BridgeBio Pharma (BBIO) Receives a Hold from Oppenheimer
Oppenheimer analyst Trevor Allred maintained a Hold rating on BridgeBio Pharma (BBIO – Research Report) today. The company’s shares opened ...